HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Nafronyl (Naftidrofuryl)

A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.

Also Known As:

Naftidrofuryl; Dusodril; Abbott Brand of Naftidrofuryl Oxalate; Alpharma Brand of Naftidrofuryl Oxalate; Artocoron; Azunaftil; Azupharma Brand of Naftidrofuryl Oxalate; Di-Actane; Faes Brand of Naftidrofuryl Oxalate; Gévatran; Hexal Brand of Naftidrofuryl Oxalate; LS-121; Lipha Brand of Naftidrofuryl Oxalate; Menarini Brand of Naftidrofuryl Oxalate; Merck Brand of Nafronyl Oxalate; Merck Lipha Santé Brand 1 of Naftidrofuryl Oxalate; Merck Lipha Santé Brand 2 of Naftidrofuryl Oxalate; Nafronyl Oxalate; Nafti-Puren; Nafti-ratiopharm; Naftifurin Oxalate; Naftilong; Naftilux; Praxilene; Praxilène; Thérabel Brand of Naftidrofuryl Oxalate; ct-Arzneimittel Brand of Naftidrofuryl Oxalate; nafti von ct; ratiopharm Brand of Naftidrofuryl Oxalate; Di Actane; DiActane; LS 121; LS121; Nafti Puren; Nafti ratiopharm; NaftiPuren; Naftiratiopharm; Oxalate, Nafronyl; Oxalate, Naftifurin; ct Arzneimittel Brand of Naftidrofuryl Oxalate; Nafronyloxalate; 2-Furanpropanoic acid, tetrahydro-alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester

Networked: 182 relevant articles (31 outcomes, 47 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 25
- 1-Ring Heterocyclic Compounds
  - Furans: 35
    - Nafronyl: 182

Experts

1.	Lehert, P: 7 articles (01/2009 - 07/2000)
2.	Mosnier, M: 3 articles (06/2001 - 07/2000)
3.	Vander Stichele, R: 2 articles (01/2009 - 01/2008)
4.	Van Bortel, L: 2 articles (01/2009 - 01/2008)
5.	Brown, T: 2 articles (03/2002 - 12/2001)
6.	Boccalon, H: 2 articles (03/2002 - 04/2001)
7.	Gamand, S: 2 articles (12/2001 - 03/2001)
8.	So, Yuen T: 1 article (02/2010)
9.	Khan, Ahmir H: 1 article (02/2010)
10.	Katzberg, Hans D: 1 article (02/2010)

Related Diseases

1.	Intermittent Claudication 03/01/2001 - "CONCLUSIONS: This study demonstrated the efficacy of naftidrofuryl versus placebo in patients with intermittent claudication with a highly significant and clinically relevant difference and confirmed its good safety profile." 04/01/2001 - "CONCLUSION: This study demonstrates the efficacy of naftidrofuryl versus placebo in patients with intermittent claudication using a new device measuring the walking distances of the patients in a more physiological way than the treadmill test." 03/01/2001 - "A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. " 01/01/2009 - "OBJECTIVE: To assess the efficacy of naftidrofuryl compared with placebo in treating the symptoms of intermittent claudication. " 03/01/2002 - "BACKGROUND: We report in this paper the findings of a pooled analysis of 3 previously published studies undertaken in Germany, France and Belgium to assess the effects of naftidrofuryl on the quality of life of patients with intermittent claudication. " Order ALL the reference details at left...
2.	Ischemia 07/01/1989 - "Ischemia-induced changes in brain levels of monoamines and their metabolites of mice and rats: some protective effects of naftidrofuryl." 01/01/1987 - "Severe stages of ischemia, evaluated as described by Fagrell, were improved by naftidrofuryl treatment. " 03/01/2001 - "Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS)." 11/01/1993 - "The present study was designed to elucidate the possible beneficial effects of naftidrofuryl on ischemia-induced endothelium damage. " 11/01/1994 - "[Evaluation of the analgesic effect of naftidrofuryl in permanent ischemia in patients with arterial diseases. " Order ALL the reference details at left...
3.	Arterial Occlusive Diseases (Arterial Occlusive Disease) 03/01/1988 - "In a randomized, double-blind, placebo-controlled study in patients with peripheral arterial occlusive disease stage IIb of Fontaine's classification, the efficacy of naftidrofuryl, a vasoactive substance, was investigated. " 01/01/1990 - "The meta-analysis confirms the beneficial effect of naftidrofuryl in treating peripheral arterial occlusive disease." 01/01/1988 - "[Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease]" 01/01/1988 - "[Effect of intravenous naftidrofuryl on the microcirculation of patients in stages III and IV of arterial occlusive disease]" 01/01/1988 - "[Capillary microscopic effect of naftidrofuryl in peripheral arterial occlusive disease]" Order ALL the reference details at left...
4.	Pain (Aches) 05/01/1980 - "Although both groups significantly increased their walking time to the onset of pain, those patients over 60 years old taking naftidrofuryl showed a significant improvement over their pretreatment walking times to onset of pain, whereas their controls did not." 04/01/1981 - "Praxilene produced subjective improvement in the symptoms of rest pain in 5 patients out of 16 in this small study." 11/01/1994 - "This study demonstrates the benefit of naftidrofuryl in pain reduction which was assessed, in particular, by the reduction of analgesic consumption." 04/01/1981 - "Naftidrofuryl for ischaemic rest pain: a controlled trial." 01/01/2000 - "MAIN RESULTS: Treatment with naftidrofuryl tended to show reduction of pain evaluated by both analogue score and analgesic consumption, but the effect was statistically non-significant (weighted mean difference -0.42, 95% confidence interval -1.19 to 0.35). " Order ALL the reference details at left...
5.	Dementia (Dementias) 07/01/2000 - "OBJECTIVE: This study examined the efficacy of naftidrofuryl in patients with vascular or mixed dementia. " 07/01/2000 - "Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial." 10/01/2000 - "The efficacy of naftidrofuryl in patients with vascular or mixed dementia." 07/01/2000 - "CONCLUSION: The results of this study suggest that naftidrofuryl is effective and well tolerated in treating the symptoms of vascular and mixed dementia." 07/01/2000 - "METHODS: This multicenter, randomized, double-blind study compared naftidrofuryl 600 mg/d with placebo for 1 year in patients with vascular or mixed dementia. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Nafronyl (Naftidrofuryl)
2.	Pain-Free
3.	buflomedil (Lofton)
4.	Pentoxifylline (Trental)
5.	Piracetam (Nootropil)
6.	Oxygen
7.	Cycloheximide (Cicloheximide)
8.	Dextrans (Dextran)
9.	Alprostadil (Muse)
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Microspheres (Microsphere)
2.	Lasers (Laser)
3.	Hemodilution
4.	Intravenous Infusions
5.	Transplantation (Transplant Recipients)

blog comments powered by Disqus

TREATMENT OPTIONS
for Intermittent Claudication,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 123 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>